Thus, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, and the monoclonal antibody against human vascular endothelial growth factor (VEGF), bevacizumab, are now components of treatment regimens for advanced NSCLC [4]. Here, VEGFA is linked to non-small cell lung carcinoma.